TSO3 Inc

TSO3 — Investor Presentation (February 2018)

22 slides from TSO3's investor presentation, Feb 22, 2018

  1. Slide 1: To Create and Deliver the New Standard of Care in Sterile Reprocessing

    To Create and Deliver the New Standard of Care in Sterile Reprocessing™ Investor Presentation | 22 February 2018 1

  2. Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures

    Important Cautions Regarding Forward Looking Statements and Other Disclosures The statements contained in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts are forward-looking statements that involve certain risks

  3. Slide 3: Vision. Purpose.

    VISION. PURPOSE. To Create and Deliver The New Standard of Care In Sterile Reprocessing™ A Sterile Device for Every Patient 3

  4. Slide 4: TSO3 Next Generation Technology

    TSO3 Next Generation Technology The STERIZONE® VP4 Sterilizer is a dual sterilant, low-temperature sterilization system that uses vaporized hydrogen peroxide (H2O2) and ozone. Features Advantages Benefits • Dual Chemistry • Simple Single Cycle • Lowest cost per Operation instrument sterilized • Dyna

  5. Slide 5: Value of a Customer

    Value of a Customer Revenue Potential Per Customer* (Assuming 2 units, 10 Yr Product Life) “Razor” Capital Equipment Sales $240k-$300k 1-4 units per facility Approx Higher-Margin Assuming 4-5 Cycles/Day, 250d/yr $0.9m-$1.2m Proprietary Consumables Revenue $50k-$62.5k/yr ~$20-30/cycle (dep. on mix an

  6. Slide 6: Breakthrough Technologies

    Breakthrough Technologies /// 138 Patents + 47 Patents Pending Worldwide 1. Insert Room Temperature Instruments Into a Warm Chamber 2. Create a Vacuum and Inject Small Amounts of Vapourized Heated Sterilant Over Time 3. Micro Condensation Forms on the Instruments Condensation Layer Dual Sterilants T

  7. Slide 7: One Core Technology – Two Markets

    Opportunity One Core Technology – Two Markets Established Base Business Emerging Opportunity Operating Room & Central Sterile Gastrointestinal Endoscope Supply Department TOTAL Reprocessing U.S. ~ 10,000 Hospitals & Ambulatory Surgery ADDRESSABLE ~15M colonoscopies performed annually2 Centers1 MARKE

  8. Slide 8: Commercialization: Original Getinge Infection Control Agreement

    Commercialization: Original Getinge Infection Control Agreement November 25, 2015 - TSO3 and Getinge Infection Control Signed Exclusive Distribution Agreement which included multi-year performance requirements and minimum annual commitments. Why TSO3 chose Getinge: • A global leader in Healthcare st

  9. Slide 9: Getinge 2016-2017

    Getinge 2016-2017 • Getinge launched sales of our STERIZONE® VP4 Sterilizer in North America and Europe. • TSO3 sold 280 STERIZONE VP4 Sterilizers to Getinge. • Simultaneously, Getinge experienced a series of organizational changes which had an impact on its businesses. • In November 2017, TSO3 disc

  10. Slide 10: Near Term Solution: TSO3 & Getinge Co-Commercialize

    Near Term Solution: TSO3 & GETINGE Co-Commercialize January 25, 2018 - TSO3 & Getinge entered into a new agreement allowing TSO3 to sell directly to and service to 50% of hospitals in North America and repurchase Getinge inventory at a discount. • Agreed to actively co-commercialize our product - TS

  11. Slide 11: Here is Why

    Here is Why Click here to open the video TSX:TOS 11

  12. Slide 12: Proven Value Proposition – Independent of Customer Size

    Proven Value Proposition – Independent of Customer Size “STERIZONE® VP4 50% less cost per “We had 4 [competitor] Sterilizers, STERIZONE® VP4 Sterilizer is 3 times instrument sterilized than now we have 2 STERIZONE® VP4 more efficient than competitor competitor” Sterilizers.” “Decreased Number of Cyc

  13. Slide 13: Commercialization Approach - CSSD

    Commercialization Approach - CSSD LEVERAGE EARLY INCREASE MARKET ESTABLISH STRONG SUPPORT WITH ADOPTERS AWARENESS CUSTOMER DIRECT SALES, TARGETING METRICS CLINICAL AND • Over 50 sterilizers TECHNICAL TSO3 to Lead Messaging • High Use Facilities installed in US and in Co-Commercialization PERSONNEL •

  14. Slide 14: Opportunity – GI Endoscopy Reprocessing

    Opportunity – GI Endoscopy Reprocessing One Core Technology – Two Markets Established Base Business Emerging Opportunity Operating Room & Central Sterile Gastrointestinal Endoscope Supply Department TOTAL Reprocessing U.S. ~10,000 Hospitals & Ambulatory Surgery ADDRESSABLE ~ 15M colonoscopies perfor

  15. Slide 15: Endoscopes & Superbugs – A Future of Sterilization

    Endoscopes & Superbugs – A Future of Sterilization SUPERBUG = Antimicrobial Resistant Bacteria 2 million+ Americans suffer from antibiotic-resistant bacteria annually – 23,000 die1 CRE is resistant to most available antibiotics - up to 50% of infected patients die2 CRE infections growing and linked

  16. Slide 16: Modernizing GI Endoscope Reprocessing

    Modernizing GI Endoscope Reprocessing Decades old processes with incremental improvement “Despite reprocessing in accordance with US guidelines, viable Old microbes and biologic debris persisted in clinically used [GI] endoscopes, suggesting current reprocessing guidelines are not sufficient to ensu

  17. Slide 17: How Change Happens

    How Change Happens Patient and Medical Technology Facility Demand Advancement • Patient Safety • STERIZONE® VP4 Sterilizer • Litigation • Cost Reduction Market Change Regulatory Change • FDA Regulation Advancement • Industry Dialogue and Guidelines TSX:TOS 17

  18. Slide 18: Duodenoscopes – Attempts to deal with Identified Risk

    Duodenoscopes – Attempts to deal with Identified Risk Pentax Medical • February 7, 2018 • Urgent Medical Device Correction and Removal (USA only) • Replace elevator mechanism, O-ring seal & distal cap • January 17, 2017 • Design issues that could lead to increased risk of infection O-ring seal • Feb

  19. Slide 19: GI Commercialization Approach

    GI Commercialization Approach Value Proposition to Hospital • Improve Patient Safety • Manage Reputational Risk • Manage Litigation Risk • Future Proofing the CSSD Evidence Based Practice: • Leverage Existing Industry Leading Claims • Colonoscopes and Gastroscopes • Higher Efficiency Processing of S

  20. Slide 20: Summary

    Next Generation Technology Extensive Patent Portfolio Razor/Razorblade Business Model SUMMARY FDA-cleared Device for Terminal Sterilization of Colonoscopes and other flexible endoscopes Co-Commercial Strategy for North America with Global Distribution Partner Financially Sound TSX:TOS 20

  21. Slide 21: Key Stats & Target Business Model

    Key Stats & Target Business Model (TSX: TOS) /// All Dollars in USD, Unless Noted Otherwise (mrq) = most recent quarter at September 30, 2017 TSX:TOS * 2017 financial data is of September 30, 2017 21

  22. Slide 22: T Sh,

    T Sh,

TSO3 — Investor Presentation (February 2018) on 6ix